-
公开(公告)号:US5248780A
公开(公告)日:1993-09-28
申请号:US951760
申请日:1992-09-25
IPC分类号: C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
摘要翻译: 本发明涉及式I的新型药学上有用的1,3-二烷基链烯酸衍生物,其在二恶烷环的第4位含有吡啶基部分,其中第2,4和5位的基团具有顺式相对立体化学,X是 氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R2是羟基,生理上可接受的醇残基或烷基磺酰氨基,及其药学上可接受的盐。 本发明还包括用于制备和使用酸衍生物的方法以及用于治疗用于一种或多种疾病如缺血性心脏病,脑血管疾病,哮喘病和/或炎性疾病的药物组合物。
-
公开(公告)号:US4745198A
公开(公告)日:1988-05-17
申请号:US797204
申请日:1985-11-12
IPC分类号: C07D319/06 , A61K31/335 , A61K31/35 , A61K31/357 , A61K31/36 , A61P7/02 , A61P9/08 , A61P9/12 , A61P11/08 , A61P43/00 , C07C20060101 , C07C59/48 , C07C69/732 , C07D309/06 , C07D317/54 , C07D319/04 , C07D319/08 , C07D325/00 , C07D407/04 , C07D407/10 , C07D413/06
CPC分类号: C07D319/08 , C07D319/06 , C07D407/04
摘要: The invention concerns novel 4-phenyl-1,3-dioxan-5-ylalkenoic acid derivatives of the formula I having cis relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonize one or more of the actions of thromboxane A.sub.2 (TXA.sub.2) and are expected to be of value in those disease conditions in which TXA.sub.2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula I, and processes for their chemical production.
-
公开(公告)号:US5612373A
公开(公告)日:1997-03-18
申请号:US266375
申请日:1994-06-27
申请人: Andrew G. Brewster , Peter W. R. Caulkett , Alan W. Faull , Robert J. Pearce , Richard E. Shute
发明人: Andrew G. Brewster , Peter W. R. Caulkett , Alan W. Faull , Robert J. Pearce , Richard E. Shute
IPC分类号: C07D295/14 , A61K31/195 , A61K31/215 , A61K31/445 , A61K31/4465 , A61P7/02 , A61P9/08 , A61P9/10 , A61P25/04 , A61P43/00 , C07C243/38 , C07C257/18 , C07D211/34 , C07D211/42 , C07D211/46 , C07D211/62 , C07D295/20 , C07D295/215 , A61K31/165 , A61K31/275 , C07C255/46
CPC分类号: C07D295/215 , C07C243/38 , C07C257/18 , C07D211/34 , C07D211/46 , C07D211/62
摘要: The invention concerns acid derivatives of formula IR.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --GIand pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
摘要翻译: 本发明涉及式IR1-CON(R2)-N(R3)CO-X1-Q-X2-GI和其药学上可接受的代谢不稳定酯或酰胺及其药学上可接受的盐的酸衍生物,其中R1,R2,R3, X1,Q,X2和G具有说明书中给出的含义。 本发明还涉及制备式I的酸衍生物的方法,含有它们的药物组合物及其作为纤维蛋白原与糖蛋白IIb / IIIa结合的抑制剂的用途。
-
公开(公告)号:US5401849A
公开(公告)日:1995-03-28
申请号:US78658
申请日:1993-06-21
IPC分类号: C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of formula VII and formula XI containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, wherein X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, Ra and Rb are independently methyl or ethyl, R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof.
摘要翻译: 本发明涉及式VII和式XI的药学上有用的1,3-二恶烷烯酸衍生物,其在二恶烷环的4位含有吡啶基部分,其中2,4和5位的基团具有顺式相对立体化学,其中X 是氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R a和R b独立地是甲基或乙基,R 2是羟基,生理上可接受的醇残基或烷基磺酰胺 ,及其药学上可接受的盐。
-
公开(公告)号:US5166213A
公开(公告)日:1992-11-24
申请号:US310235
申请日:1989-02-14
IPC分类号: A61K31/44 , A61K31/443 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/08 , A61P29/00 , A61P43/00 , C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
-
公开(公告)号:US4921866A
公开(公告)日:1990-05-01
申请号:US185873
申请日:1988-04-25
IPC分类号: A61K31/44 , A61K31/443 , A61P7/04 , A61P9/00 , A61P11/00 , C07D405/04 , C07D405/06 , C07D405/12
CPC分类号: C07D405/04 , C07D405/06 , C07D405/12
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkanoic and alkenoic acid derivatives of the formula I in which the groups at positions 2, 4 and 5 of the 1,3-dioxane ring have cis-relative stereochemistry, Y is ethylene or vinylene, n is 1-4, Z is hydrogen or hydroxy, and X is a pyridine containing group (as defined hereinafter); and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
-
7.
公开(公告)号:US5274118A
公开(公告)日:1993-12-28
申请号:US803291
申请日:1991-12-04
IPC分类号: A61K31/40 , A61K31/403 , A61K31/404 , A61P11/00 , A61P37/08 , C07C209/50 , C07C211/15 , C07C211/27 , C07C231/18 , C07C233/05 , C07C311/15 , C07C311/17 , C07D209/24 , C07B57/00
CPC分类号: C07C209/50 , C07C211/15 , C07C231/18 , C07D209/24
摘要: A process for the preparation of (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof which comprisesa) acylating an optically active amine with 2-methyl-4,4,4-trifluorobutanoic acid or a reactive derivative thereof to afford a butyramide;b) separating (R)-diastereomeric butyramide from (S)-diastereomeric butyramide; andc) converting the (R)-diastereomeric butyramide into the desired (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof. The product may be acylated with a carboxylic acid of formula III ##STR1## wherein U is carboxy, or a reactive derivative thereof to afford (R)-4-[5-(N-[4,4,4-trifluoro-2-methylbutyl]carbamoyl)-1-methylindol-3-yl-methyl]-3-methoxy-N-o-tolylsulphonylbenzamide. The indole is useful as a leukotriene antagonist, for example in the treatment of asthma or allergic rhinitis.
摘要翻译: 一种制备(2R) - 甲基-4,4,4-三氟丁胺或其酸加成盐的方法,其包括:a)用2-甲基-4,4,4-三氟丁酸或 其反应性衍生物得到丁酰胺; b)从(S) - 非对映异丁基丁酰胺分离(R) - 非对映异构体丁酰胺; 和(c)将(R) - 非对映异构体丁酰胺转化为所需的(2R) - 甲基-4,4,4-三氟丁胺或其酸加成盐。 产物可以用其中U是羧基的式III的羧酸或其活性衍生物酰化,得到(R)-4- [5-(N- [4,4,4-三氟 -2-甲基丁基]氨基甲酰基)-1-甲基吲哚-3-基 - 甲基] -3-甲氧基 - 甲苯磺酰基苯甲酰胺。 吲哚可用作白三烯拮抗剂,例如用于治疗哮喘或过敏性鼻炎。
-
公开(公告)号:US4895963A
公开(公告)日:1990-01-23
申请号:US217851
申请日:1988-07-12
IPC分类号: A61K31/335 , A61K31/357 , A61P7/02 , A61P9/08 , C07D319/06
CPC分类号: C07D319/06
摘要: The invention provides a novel group of 4(Z)-6-([2,4,5-cis]-2-alkyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I wherein R is branched alkyl or 3-5 carbon atoms and one of X and Y is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of the novel compounds. A representative compound is that in which R is t-butyl and X and Y are both hydrogen.
-
公开(公告)号:US4772625A
公开(公告)日:1988-09-20
申请号:US861330
申请日:1986-05-09
IPC分类号: A61K31/335 , A61K31/357 , A61P7/02 , A61P9/08 , C07D319/06
CPC分类号: C07D319/06
摘要: The invention provides a novel group of 4(Z)-6-([2,4,5-cis]-2-alkyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I wherein R is branched alkyl of 3-5 carbon atoms and one of X and Y is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of the novel compounds. A representative compound is that in which R is t-butyl ans X and Y are both hydrogen.
摘要翻译: 本发明提供了式I的4(Z)-6 - ([2,4,5-顺式] -2-烷基-4-邻羟基苯基-1,3-二恶烷-5-基)己烯酸的新一组 其中R是3-5个碳原子的支链烷基,X和Y之一是氢或氟,另一个是氢,及其药学上可接受的盐; 以及用于治疗各种疾病状况的药物组合物。 还提供了用于制备新型化合物的方法。 代表性化合物是其中R是叔丁基,X和Y都是氢的化合物。
-
公开(公告)号:US5563141A
公开(公告)日:1996-10-08
申请号:US218174
申请日:1994-03-28
申请人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Stuart D. Mills , Peter W. R. Caulkett
发明人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Stuart D. Mills , Peter W. R. Caulkett
IPC分类号: A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/445 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K31/5377 , A61P7/02 , A61P43/00 , C07D213/74 , C07D213/81 , C07D215/14 , C07D215/42 , C07D239/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D521/00 , A61K31/495 , C07D401/00 , C07D403/00 , C07D405/00
CPC分类号: C07D213/74 , C07D213/81 , C07D215/42 , C07D239/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12
摘要: A compound of the general formula(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A Iwherein:n is 0 or 1;M.sup.1 is an amino group;Q is an aromatic heterocyclic group containing a basic nitrogen atom;M.sup.2 is an imino group;L is a template group; andA is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group;and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.
摘要翻译: 通式(M1)n-Q-(M2)1-n-L-1的化合物,其中n为0或1; M1是氨基; Q是含有碱性氮原子的芳香族杂环基; M2是亚氨基; L是模板组; A是酸性基团,或其酯或酰胺衍生物或磺酰胺基团; 和其药学上可接受的盐和前药,用于治疗由粘附分子与GPIIb-IIIa的结合介导的血小板聚集的疾病。 还公开了新的化合物。
-
-
-
-
-
-
-
-
-